News

Hosted on MSN3d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
KDFW3d
Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Ibj.com7d
Lilly’s Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.